lifestyle.longislandreport.org

Author: AbbVie Inc.

AbbVie Announces Topline Results for Epcoritamab (DuoBody® CD3xCD20) from Phase 3 EPCORE® DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)

January 20, 2026
AbbVie Announces Topline Results for Epcoritamab (DuoBody® CD3xCD20) from Phase 3 EPCORE® DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)

January 20, 2026
AbbVie and Trump Administration Reach Agreement to Improve Access and Affordability for Americans

January 12, 2026
AbbVie and RemeGen Announce Exclusive Licensing Agreement to Develop A Novel Bispecific Antibody for Advanced Solid Tumors

January 12, 2026
AbbVie to Acquire Arizona Manufacturing Facility, Further Strengthening Manufacturing Capabilities in the United States

January 12, 2026
AbbVie to Host Full-Year and Fourth-Quarter 2025 Earnings Conference Call

January 7, 2026
AbbVie to Present at the 44th Annual J.P. Morgan Healthcare Conference

January 5, 2026
AbbVie to Present at the Piper Sandler 37th Annual Healthcare Conference

November 24, 2025
AbbVie Partners with Award-Winning Filmmaker on Film About the Dynamic and Resilient Lives of Those Living with Blood Cancer

November 18, 2025
Allergan Aesthetics Unveils New Data at 2025 American Society for Dermatologic Surgery Annual Meeting Showcasing Transformative Innovation and Portfolio Excellence

November 17, 2025